title: Systemic treatment for hereditary cancers: a 2012 update.
abstract: The history of specific therapy for hereditary tumors dates back to mid 1980s and involves a number of reports demonstrating regression of familial colon polyps upon administration of sulindac. Virtually no clinical studies on other hereditary cancer types were available until the year 2009, when Byrski et al. presented the data on unprecedented sensitivity of BRCA1-associated breast malignancies to cisplatin. This breakthrough has revived interest to the treatment of cancer in germ-line mutation carriers. Recent trials and clinical observations have confirmed the efficacy of platinating agents and PARP inhibitors in BRCA1/2-driven breast, ovarian and pancreatic carcinomas. Pegylated liposomal doxorubicin may be considered as a promising treatment option for BRCA1/2-related ovarian cancer after the failure of platinum-containing therapy. Several novel drugs have been recently introduced in the management of rare familial tumor syndromes. Vandetanib, a low-molecular weight RET kinase inhibitor, demonstrated substantial efficacy in the treatment of hereditary and sporadic medullary thyroid cancer. Vismodegib, an inhibitor of SMO oncoprotein, caused regression of basal-cell carcinomas in patients with Gorlin syndrome. Down-regulation of mTOR kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. The achievements in the prevention, diagnostics and treatment of hereditary cancers may serve as an excellent example of triumph of translational medicine.
authors.affiliation: Laboratory of Molecular Oncology, NN Petrov Institute of Oncology, St,-Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru.
authors.forename: Evgeny N
authors.initials: EN
authors.lastname: Imyanitov
authors.forename: Tomasz
authors.initials: T
authors.lastname: Byrski
references.citation: J Clin Oncol. 2010 Feb 10;28(5):767-72
references.pmid: 20065189
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3570-6
references.pmid: 20606085
references.citation: J Clin Oncol. 2012 Jan 10;30(2):134-41
references.pmid: 22025146
references.citation: J Clin Pathol. 2011 Oct;64(10):924-6
references.pmid: 21378390
references.citation: Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8
references.pmid: 21987798
references.citation: Ann Surg Oncol. 2007 Sep;14(9):2428-9
references.pmid: 17406948
references.citation: Gynecol Oncol. 2011 Nov;123(2):196-9
references.pmid: 21855118
references.citation: Arch Med Sci. 2012 May 9;8(2):310-5
references.pmid: 22662005
references.citation: Breast Cancer Res. 2012 Jul 20;14(4):R110
references.pmid: 22817698
references.citation: Gynecol Oncol. 2011 Dec;123(3):486-91
references.pmid: 21945552
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4224-6
references.pmid: 21931031
references.citation: Mol Cancer Ther. 2011 Oct;10(10):2000-7
references.pmid: 21835933
references.citation: Cancer Genet Cytogenet. 2010 Feb;197(1):91-4
references.pmid: 20113845
references.citation: Hered Cancer Clin Pract. 2009 Apr 20;7(1):8
references.pmid: 19379506
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3739-46
references.pmid: 21900106
references.citation: Oncologist. 2008 Aug;13(8):859-75
references.pmid: 18701762
references.citation: Hered Cancer Clin Pract. 2011 Aug 06;9(1):5
references.pmid: 21819606
references.citation: Oncologist. 2011;16(10):1397-402
references.pmid: 21934105
references.citation: J Clin Oncol. 2010 Jan 20;28(3):375-9
references.pmid: 20008645
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2654-63
references.pmid: 22711857
references.citation: Anticancer Res. 2011 Apr;31(4):1417-20
references.pmid: 21508395
references.citation: N Engl J Med. 2012 Jun 7;366(23):2180-8
references.pmid: 22670904
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3008-15
references.pmid: 21709188
references.citation: J Surg Oncol. 1983 Sep;24(1):83-7
references.pmid: 6887943
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Cancer. 2012 Feb 15;118(4):899-907
references.pmid: 21761396
references.citation: Clin Cancer Res. 2010 Jan 1;16(1):99-108
references.pmid: 20008842
references.citation: Fam Cancer. 2010 Sep;9(3):289-90
references.pmid: 20054658
references.citation: Lancet Oncol. 2011 Sep;12(9):852-61
references.pmid: 21862407
references.citation: Cancer J. 2012 Jul-Aug;18(4):287-92
references.pmid: 22846728
references.citation: Nat Rev Clin Oncol. 2010 Dec;7(12):702-7
references.pmid: 20956982
references.citation: Ann Oncol. 2011 Jun;22(6):1346-1352
references.pmid: 21228333
references.citation: Nat Rev Clin Oncol. 2009 Aug;6(8):488-92
references.pmid: 19644536
references.citation: J Natl Cancer Inst. 2011 Jun 8;103(11):863-75
references.pmid: 21597022
references.citation: Breast Cancer Res Treat. 2009 May;115(2):359-63
references.pmid: 18649131
references.citation: Mol Cancer Ther. 2011 Jan;10(1):3-8
references.pmid: 21135251
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references.pmid: 20100965
references.citation: J Clin Oncol. 2012 Feb 1;30(4):372-9
references.pmid: 22203755
references.citation: Cancer Biol Ther. 2011 Aug 1;12(3):165-8
references.pmid: 21613821
references.citation: N Engl J Med. 2010 Nov 4;363(19):1801-11
references.pmid: 21047224
references.citation: Nat Rev Clin Oncol. 2010 Mar;7(3):153-62
references.pmid: 20142816